NEW YORK, Dec. 12, 2017 /PRNewswire/ --
In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on OSUR, HRC, TNDM, and MZOR which is a click away at www.wallstequities.com/registration. Today, WallStEquities.com covers the performance of these Medical Instruments and Supplies stocks: OraSure Technologies Inc. (NASDAQ : OSUR ), Hill-Rom Holdings Inc. (NYSE : HRC ), Tandem Diabetes Care Inc. (NASDAQ : TNDM ), and Mazor Robotics Ltd (NASDAQ : MZOR ). Medical Instruments and Supplies companies primarily research, develop, and produce nonelectronic medical, surgical, dental, and veterinary instruments and apparatus, such as syringes, anesthesia apparatus, and blood transfusion equipment, among many others. Wall St. Equities has a wide array of free research reports which include today's stock picks, register now to access them at: www.wallstequities.com/registration
On Monday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. recorded a trading volume of 685,075 shares. The stock ended at $17.34, declining 0.17% from the last trading session. The Company's shares have gained 21.00% in the last one month and 97.49% on an YTD basis. The stock is trading above its 200-day moving average by 3.45%. Furthermore, shares of OraSure Technologies, which together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the US, Europe, and internationally, have a Relative Strength Index (RSI) of 53.68.
On December 08th, 2017, OraSure Technologies announced that its 2018 Annual Meeting of Stockholders is scheduled on May 08th, 2018, at 10:00 a.m. EDT. This will be a completely virtual meeting, conducted as a live webcast. Further details regarding the meeting will be provided at a later date. Follow the link below to your free research report on OSUR at: www.wallstequities.com/registration/?symbol=OSUR
Chicago, Illinois headquartered Hill-Rom Holdings Inc.'s stock finished yesterday's session 0.43% lower at $82.84 with a total trading volume of 277,097 shares. The Company's shares have gained 6.25% in the last one month, 6.77% over the previous three months, and 47.56% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 3.70% and 8.71%, respectively. Furthermore, shares of Hill-Rom, which operates as a medical technology company worldwide, have an RSI of 56.80.
On November 27th, 2017, Hill-Rom Holdings (HRC) and IMRIS announced that HRC's Trumpf Medical has completed device listing and registration with the US FDA for a new, multi-functional operating room table specifically designed for the IMRIS Surgical Theatre. This innovative joint development integrates a new IMRIS MR Neuro tabletop and HRC's TruSystem® 7500 Surgical Table platform with the IMRIS Surgical Theatre to support better patient treatment. The free technical report on HRC can be accessed at: www.wallstequities.com/registration/?symbol=HRC
Tandem Diabetes Care
At the close of trading on Monday, shares in San Diego, California headquartered Tandem Diabetes Care Inc. rose 3.33%, ending the day at $2.48. The stock recorded a trading volume of 142,743 shares. The Company's shares are trading 27.13% below their 50-day moving average. Moreover, shares of the Company, which designs, develops, and commercializes various products for people with insulin-dependent diabetes in the US, have an RSI of 37.50.
On December 07th, 2017, Tandem Diabetes Care announced the retirement of its Executive Vice President and CFO, John Cajigas, effective December 31st, 2017. Leigh Vosseller, who is currently serving as Senior Vice President of finance, will be promoted to CFO, effective January 01st, 2018. Sign up for free on Wall St. Equities and claim the latest report on TNDM at: www.wallstequities.com/registration/?symbol=TNDM
Caesarea, Israel-based Mazor Robotics Ltd's shares ended the day 2.04% higher at $54.12 with a total trading volume of 325,372 shares. The stock has gained 20.29% over the previous three months and 146.90% on an YTD basis. The Company's shares are trading 30.59% above their 200-day moving average. Additionally, shares of Mazor Robotics, which together with its subsidiary, Mazor Robotics Inc., is engaged in the development, production, marketing, and servicing of medical devices for supporting surgical procedures in the fields of orthopedics and neurosurgery in the US, Western Europe, Eastern Europe, and Asia, have an RSI of 42.49. See the free research coverage on MZOR at: www.wallstequities.com/registration/?symbol=MZOR
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities